Rosario Distefano
Overview
Explore the profile of Rosario Distefano including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
349
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tomasello L, Holub S, Nigita G, Distefano R, Croce C
Signal Transduct Target Ther
. 2024 Apr;
9(1):90.
PMID: 38616203
No abstract available.
2.
Rampioni Vinciguerra G, Capece M, Reggiani Bonetti L, Nigita G, Calore F, Rentsch S, et al.
Signal Transduct Target Ther
. 2024 Feb;
9(1):31.
PMID: 38342897
Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease, characterized by an intense desmoplastic reaction that compresses blood vessels and limits nutrient supplies. PDAC aggressiveness largely relies on its extraordinary capability...
3.
La Ferlita A, Alaimo S, Nigita G, Distefano R, Beane J, Tsichlis P, et al.
iScience
. 2024 Feb;
27(2):108810.
PMID: 38303722
tRNA-derived ncRNAs are a heterogeneous class of non-coding RNAs recently proposed to be active regulators of gene expression and be involved in many diseases, including cancer. Consequently, several online resources...
4.
Saviana M, Romano G, McElroy J, Nigita G, Distefano R, Toft R, et al.
Front Oncol
. 2023 Oct;
13:1255527.
PMID: 37869089
Introduction: Small cell lung cancer (SCLC) is characterized by poor prognosis and challenging diagnosis. Screening in high-risk smokers results in a reduction in lung cancer mortality, however, screening efforts are...
5.
Rajendran S, Hu Y, Canella A, Peterson C, Gross A, Cam M, et al.
Cell Rep
. 2023 Mar;
42(3):112197.
PMID: 36871221
Recent studies have shown the importance of the dynamic tumor microenvironment (TME) in high-grade gliomas (HGGs). In particular, myeloid cells are known to mediate immunosuppression in glioma; however, it is...
6.
Rampioni Vinciguerra G, Capece M, Distefano R, Nigita G, Vecchione A, Lovat F, et al.
Signal Transduct Target Ther
. 2023 Jan;
8(1):37.
PMID: 36702817
No abstract available.
7.
Lai T, Ozer H, Gasparini P, Nigita G, Distefano R, Yu L, et al.
Blood Adv
. 2022 Oct;
7(12):2897-2911.
PMID: 36287107
Chronic lymphocytic leukemia (CLL) is a quiescent B-cell malignancy that depends on transcriptional dysregulation for survival. The histone deacetylases are transcriptional regulators whose role within the regulatory chromatin and consequence...
8.
La Ferlita A, Distefano R, Alaimo S, Beane J, Ferro A, Croce C, et al.
Cancers (Basel)
. 2022 Sep;
14(18).
PMID: 36139593
Lung cancer is the second most commonly diagnosed cancer and the leading cause of cancer deaths worldwide. Among its subtypes, lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) are...
9.
Distefano R, Tomasello L, Rampioni Vinciguerra G, Gasparini P, Xiang Y, Bagnoli M, et al.
Cancer Res
. 2022 Aug;
82(20):3687-3700.
PMID: 36040379
Significance: Modified miRNAs may act as cancer biomarkers and function as allies or antagonists of their canonical counterparts in gene regulation, suggesting the concurrent consideration of canonical and modified miRNAs...
10.
Distefano R, Nigita G, Le P, Romano G, Acunzo M, Nana-Sinkam P
Cancers (Basel)
. 2022 Feb;
14(3).
PMID: 35159038
Despite the development of targeted therapeutics, immunotherapy, and strategies for early detection, lung cancer carries a high mortality. Further, significant racial disparities in outcomes exist for which the molecular drivers...